Clinical Cancer Research highlights OncoSec's Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue Feb 04, 2020 8:30am EST
OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting Feb 03, 2020 8:46am EST
OncoSec Urges Shareholders to Focus on the Critical Benefits of CGP/Sirtex Transaction Jan 31, 2020 8:30am EST
OncoSec Urges Shareholders Not to Fall for Alpha’s Disingenuous “Proposal” and Scheme to Prevent Fair Vote at Special Meeting Jan 28, 2020 8:30am EST
Data from OncoSec's Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting Jan 27, 2020 8:30am EST
OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller Jan 21, 2020 4:30pm EST
OncoSec Board Rejects Alpha Holdings “Proposal” and Announces New Special Meeting Date Jan 16, 2020 8:30am EST
OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Have Recommended That OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card Jan 06, 2020 8:30am EST
Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction Dec 26, 2019 8:30am EST
